Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parkinson disease: an update.

Steven J Frucht1

  • 1Columbia-Presbyterian Medical Center, New York, NY 10032, USA. sf216@columbia.edu

The Neurologist
|July 13, 2004
PubMed
Summary

New Parkinson disease (PD) medications offer improved management of motor and nonmotor symptoms. This review details current and emerging treatments to help neurologists navigate PD therapy options effectively.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point of view: Task-specific movement disorders-time for a reappraisal?

Parkinsonism & related disorders·2026
Same author

RRP12 Variants Are Associated With Autosomal Recessive Brain Calcifications.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Myoclonus, dystonia and parkinsonism due to a de novo novel variant in the NUS1 gene: Furthering the epilepsy-dyskinesia spectrum - Expert commentary.

Parkinsonism & related disorders·2025
Same author

Deep Phenotyping of Musicians' Upper Limb Dystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)·2025
Same author

The Spectrum of Neurologic Phenotypes Associated With NUS1 Pathogenic Variants: A Comprehensive Case Series.

Annals of neurology·2025
Same author

Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).

Movement disorders : official journal of the Movement Disorder Society·2025

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson disease (PD) treatment has evolved significantly over the last decade.
  • Introduction of novel drugs for both cardinal motor symptoms and nonmotor manifestations.
  • Clinicians face challenges in managing the expanding array of PD medications.

Observation:

  • This review summarizes recently approved PD medications, including dopamine agonists and catechol-O-methyl-transferase inhibitors.
  • It addresses agents for common nonmotor issues like hallucinations, orthostasis, nausea, erectile dysfunction, depression, and memory loss.
  • Case histories illustrate practical management strategies for PD patients.

Findings:

  • Neurologists possess a broad range of therapeutic options for PD.
  • Current treatments effectively manage both motor and nonmotor aspects of the disease.
  • Promising new drugs are under development for future PD treatment.

Implications:

  • Understanding the current and emerging pharmacopeia is crucial for optimizing PD patient care.
  • Effective management of both motor and nonmotor symptoms can significantly improve patient quality of life.
  • This review serves as a guide for clinicians to navigate complex PD treatment landscapes.

Related Experiment Videos